177 related articles for article (PubMed ID: 28369758)
41. Molecular Profiling of Pediatric and Adult Glioblastoma.
Gestrich CK; Jajosky AN; Elliott R; Stearns D; Sadri N; Cohen ML; Couce ME
Am J Clin Pathol; 2021 Mar; 155(4):606-614. PubMed ID: 33210143
[TBL] [Abstract][Full Text] [Related]
42. Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019.
Suerink M; Wimmer K; Brugieres L; Colas C; Gallon R; Ripperger T; Benusiglio PR; Bleiker EMA; Ghorbanoghli Z; Goldberg Y; Hardwick JCH; Kloor M; le Mentec M; Muleris M; Pineda M; Ruiz-Ponte C; Vasen HFA
Fam Cancer; 2021 Jan; 20(1):67-73. PubMed ID: 32613597
[No Abstract] [Full Text] [Related]
43. Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome.
Galuppini F; Opocher E; Tabori U; Mammi I; Edwards M; Campbell B; Kelly J; Viel A; Quaia M; Rivieri F; D'Avella D; Arcella A; Giangaspero F; Fassan M; Gardiman MP
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):233-239. PubMed ID: 29130549
[No Abstract] [Full Text] [Related]
44. Ongoing issues with the management of children with Constitutional Mismatch Repair Deficiency syndrome.
Farah RA; Maalouf F; Chahine NA; Farhat H; Campbell B; Zhukova N; Durno C; Aronson M; Hawkins C; Bouffet E; Tabori U
Eur J Med Genet; 2019 Aug; 62(8):103706. PubMed ID: 31233827
[TBL] [Abstract][Full Text] [Related]
45. Constitutional mismatch repair deficiency and Lynch syndrome among consecutive Arab Bedouins with colorectal cancer in Israel.
Abu Freha N; Leibovici Weissman Y; Fich A; Barnes Kedar I; Halpern M; Sztarkier I; Behar DM; Arbib Sneh O; Vilkin A; Baris HN; Gingold R; Lejbkowicz F; Niv Y; Goldberg Y; Levi Z
Fam Cancer; 2018 Jan; 17(1):79-86. PubMed ID: 28608265
[TBL] [Abstract][Full Text] [Related]
46. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency.
Wimmer K; Beilken A; Nustede R; Ripperger T; Lamottke B; Ure B; Steinmann D; Reineke-Plaass T; Lehmann U; Zschocke J; Valle L; Fauth C; Kratz CP
Fam Cancer; 2017 Jan; 16(1):67-71. PubMed ID: 27573199
[TBL] [Abstract][Full Text] [Related]
47. Metachronous T-Lymphoblastic Lymphoma and Burkitt Lymphoma in a Child With Constitutional Mismatch Repair Deficiency Syndrome.
Alexander TB; McGee RB; Kaye EC; McCarville MB; Choi JK; Cavender CP; Nichols KE; Sandlund JT
Pediatr Blood Cancer; 2016 Aug; 63(8):1454-6. PubMed ID: 27037742
[TBL] [Abstract][Full Text] [Related]
48. B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency.
Oshrine B; Grana N; Moore C; Nguyen J; Crenshaw M; Edwards M; Sudhaman S; Forster VJ; Tabori U
Blood Adv; 2019 Jun; 3(12):1795-1798. PubMed ID: 31189528
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD).
Wimmer K; Kratz CP; Vasen HF; Caron O; Colas C; Entz-Werle N; Gerdes AM; Goldberg Y; Ilencikova D; Muleris M; Duval A; Lavoine N; Ruiz-Ponte C; Slavc I; Burkhardt B; Brugieres L;
J Med Genet; 2014 Jun; 51(6):355-65. PubMed ID: 24737826
[TBL] [Abstract][Full Text] [Related]
50. CSF cytology diagnosis of NRAS-mutated primary leptomeningeal melanomatosis with neurocutaneous melanosis.
Kolin DL; Geddie WR; Ko HM
Cytopathology; 2017 Jun; 28(3):235-238. PubMed ID: 27696542
[No Abstract] [Full Text] [Related]
51. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome.
van der Klift HM; Mensenkamp AR; Drost M; Bik EC; Vos YJ; Gille HJ; Redeker BE; Tiersma Y; Zonneveld JB; García EG; Letteboer TG; Olderode-Berends MJ; van Hest LP; van Os TA; Verhoef S; Wagner A; van Asperen CJ; Ten Broeke SW; Hes FJ; de Wind N; Nielsen M; Devilee P; Ligtenberg MJ; Wijnen JT; Tops CM
Hum Mutat; 2016 Nov; 37(11):1162-1179. PubMed ID: 27435373
[TBL] [Abstract][Full Text] [Related]
52. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1.
Krüger S; Kinzel M; Walldorf C; Gottschling S; Bier A; Tinschert S; von Stackelberg A; Henn W; Görgens H; Boue S; Kölble K; Büttner R; Schackert HK
Eur J Hum Genet; 2008 Jan; 16(1):62-72. PubMed ID: 17851451
[TBL] [Abstract][Full Text] [Related]
53. Hereditary colorectal cancer syndromes and genetic testing.
Macaron C; Leach BH; Burke CA
J Surg Oncol; 2015 Jan; 111(1):103-11. PubMed ID: 24975382
[TBL] [Abstract][Full Text] [Related]
54. Identification of a novel PMS2 alteration c.505C>G (R169G) in trans with a PMS2 pathogenic mutation in a patient with constitutional mismatch repair deficiency.
Mork ME; Borras E; Taggart MW; Cuddy A; Bannon SA; You YN; Lynch PM; Ramirez PT; Rodriguez-Bigas MA; Vilar E
Fam Cancer; 2016 Oct; 15(4):587-91. PubMed ID: 27017610
[TBL] [Abstract][Full Text] [Related]
55. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome.
Ripperger T; Schlegelberger B
Eur J Med Genet; 2016 Mar; 59(3):133-42. PubMed ID: 26743104
[TBL] [Abstract][Full Text] [Related]
56. Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium.
Aronson M; Gallinger S; Cohen Z; Cohen S; Dvir R; Elhasid R; Baris HN; Kariv R; Druker H; Chan H; Ling SC; Kortan P; Holter S; Semotiuk K; Malkin D; Farah R; Sayad A; Heald B; Kalady MF; Penney LS; Rideout AL; Rashid M; Hasadsri L; Pichurin P; Riegert-Johnson D; Campbell B; Bakry D; Al-Rimawi H; Alharbi QK; Alharbi M; Shamvil A; Tabori U; Durno C
Am J Gastroenterol; 2016 Feb; 111(2):275-84. PubMed ID: 26729549
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
[TBL] [Abstract][Full Text] [Related]
58. Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene.
De Rosa M; Fasano C; Panariello L; Scarano MI; Belli G; Iannelli A; Ciciliano F; Izzo P
Oncogene; 2000 Mar; 19(13):1719-23. PubMed ID: 10763829
[TBL] [Abstract][Full Text] [Related]
59. PMS2 mutations in childhood cancer.
Bonthron DT; Hayward BE; De Vos M; Sheridan E
Gut; 2005 Dec; 54(12):1821. PubMed ID: 16284300
[No Abstract] [Full Text] [Related]
60. Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?
Patel J; Salgado CM; Múgica MR; Basu D
Neuro Oncol; 2016 Jan; 18(1):142-3. PubMed ID: 26667139
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
